Additional file 3: of Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and poor prognosis due to red blood cell transfusion–dependent anemia and thrombocytopenia

Supplementary Appendix for Protocol AZA-MDS-003, Amendment number 2.0, (08 Oct 2015). (DOCX 39 kb)